Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab Govitecan | Approved | Phase 3 | 92 | 50 | 22 | 115 | 13 | CA, EU, US | Apr 22, 2020 | Dec 17, 2012 |
| Ibrutinib | Approved | Phase 4 | 84 | 20 | 39 | 277 | 41 | CA, EU, US | Nov 13, 2013 | 2009-02 |
| Blinatumomab | Approved | Phase 4 | 83 | 41 | 24 | 137 | 13 | CA, EU, US | Dec 3, 2014 | 2004-06 |
| Melphalan | Approved | Phase 4 | 80 | 38 | 82 | 571 | 13 | CA, EU, US | Dec 31, 1964 | 1990-07 |
| Zanubrutinib | Approved | Phase 4 | 80 | 43 | 14 | 114 | 23 | CA, EU, US | Nov 14, 2019 | Sep 4, 2014 |
| Acalabrutinib | Approved | Phase 4 | 79 | 30 | 19 | 113 | 15 | CA, EU, US | Oct 31, 2017 | Jan 30, 2014 |
| Carfilzomib | Approved | Phase 4 | 73 | 25 | 28 | 200 | 14 | CA, EU, US | Jul 20, 2012 | 2005-09 |
| Ruxolitinib | Approved | Phase 4 | 73 | 43 | 18 | 173 | 20 | CA, EU, US | Nov 16, 2011 | Sep 26, 2002 |
| Bendamustine | Approved | Phase 4 | 71 | 29 | 65 | 279 | 31 | CA, US | Mar 20, 2008 | 2001-09 |
| Everolimus | Approved | Phase 4 | 70 | 29 | 54 | 509 | 31 | EU, US | Mar 30, 2009 | Nov 13, 2002 |
| Decitabine | Approved | Phase 4 | 70 | 35 | 35 | 285 | 6 | CA, EU, US | Sep 20, 2012 | 1995-08 |
| Serplulimab | Approved | Phase 4 | 68 | 35 | 15 | 95 | 1 | EU | Feb 3, 2025 | Feb 14, 2018 |
| Topotecan | Approved | Phase 4 | 67 | 37 | 84 | 367 | 29 | CA, EU, US | May 28, 1996 | 1992-10 |
| Trametinib | Approved | Phase 4 | 67 | 24 | 13 | 214 | 33 | CA, EU, US | May 29, 2013 | Jul 28, 2008 |
| Tremelimumab | Approved | Phase 3 | 67 | 24 | 19 | 188 | 5 | CA, EU, US | Oct 21, 2022 | 2003-08 |
| Ribociclib | Approved | Phase 4 | 65 | 33 | 24 | 144 | 11 | CA, EU, US | Mar 13, 2017 | Dec 21, 2010 |
| Niraparib | Approved | Phase 4 | 64 | 27 | 18 | 163 | 9 | CA, EU, US | Nov 16, 2017 | 2008-09 |
| Aldesleukin | Approved | Phase 4 | 60 | 41 | 29 | 397 | 5 | CA, US | May 5, 1992 | 1991-04 |
| Selinexor | Approved | Phase 4 | 60 | 30 | 16 | 148 | 7 | CA, EU, US | Jul 3, 2019 | Jun 18, 2012 |
| Daunorubicin | Approved | Phase 4 | 58 | 36 | 87 | 249 | 9 | CA, EU, US | Dec 31, 1971 | 1986-11 |
| Dostarlimab | Approved | Phase 4 | 58 | 21 | 12 | 87 | 8 | CA, EU, US | Apr 21, 2021 | Mar 7, 2016 |
| Glofitamab | Approved | Phase 3 | 58 | 25 | 4 | 69 | 4 | CA, EU, US | Jun 15, 2023 | Feb 21, 2017 |
| Metformin | Approved | Phase 4 | 56 | 28 | 52 | 365 | 3 | US | Sep 11, 2003 | Jul 31, 1996 |
| Regorafenib | Approved | Phase 4 | 56 | 28 | 30 | 215 | 7 | CA, EU, US | Sep 27, 2012 | Apr 30, 2008 |
| Enfortumab Vedotin | Approved | Phase 4 | 56 | 36 | 10 | 69 | 12 | CA, EU, US | Dec 18, 2019 | Jul 11, 2011 |
| Tamoxifen | Approved | Phase 4 | 55 | 29 | 116 | 287 | 31 | CA, US | Dec 31, 1989 | 1987-09 |
| Darolutamide | Approved | Phase 4 | 54 | 30 | 20 | 82 | 6 | CA, EU, US | Jul 30, 2019 | 2011-03 |
| Busulfan | Approved | Phase 4 | 53 | 22 | 52 | 371 | 11 | CA, EU, US | Jun 26, 1954 | 1987-08 |
| Epcoritamab | Approved | Phase 3 | 53 | 30 | 6 | 57 | 8 | CA, EU, US | May 19, 2023 | Jun 26, 2018 |
| Sirolimus | Approved | Phase 4 | 52 | 26 | 24 | 228 | 16 | US | Sep 15, 1999 | 1996-03 |
| Avelumab | Approved | Phase 3 | 51 | 12 | 18 | 223 | 12 | CA, EU, US | Mar 23, 2017 | Jan 31, 2013 |
| Ifosfamide | Approved | Phase 4 | 50 | 23 | 79 | 313 | 8 | CA, US | Aug 14, 1987 | 1990-05 |
| Teclistamab | Approved | Phase 4 | 50 | 28 | 11 | 53 | 7 | CA, EU, US | Aug 23, 2022 | May 16, 2017 |
| Isatuximab | Approved | Phase 3 | 49 | 21 | 13 | 67 | 10 | CA, EU, US | Mar 2, 2020 | Jan 21, 2015 |
| Filgrastim | Approved | Phase 4 | 48 | 25 | 132 | 763 | 34 | CA, EU, US | Feb 20, 1991 | 1988-03 |
| Anastrozole | Approved | Phase 4 | 48 | 21 | 63 | 186 | 39 | CA, US | Dec 27, 1995 | 1996-01 |
| Abiraterone Acetate | Approved | Phase 4 | 48 | 17 | 23 | 148 | 41 | CA, EU, US | Apr 28, 2011 | 2005-11 |
| Vinorelbine | Approved | Phase 4 | 47 | 25 | 89 | 311 | 10 | CA, US | May 9, 2007 | 1995-02 |
| Epirubicin | Approved | Phase 4 | 46 | 24 | 104 | 282 | 17 | CA, US | Sep 15, 1999 | 1991-10 |
| Apalutamide | Approved | Phase 4 | 46 | 19 | 20 | 93 | 8 | CA, EU, US | Feb 14, 2018 | Feb 5, 2013 |
| Dasatinib | Approved | Phase 4 | 45 | 19 | 19 | 268 | 43 | CA, EU, US | Jun 28, 2006 | Jul 13, 2001 |
| Eribulin | Approved | Phase 4 | 45 | 20 | 30 | 157 | 12 | CA, EU, US | Nov 15, 2010 | 2002-08 |
| Abiraterone | Approved | Phase 4 | 45 | 24 | 19 | 103 | 8 | EU, US | Apr 28, 2011 | Jul 8, 2005 |
| Polatuzumab Vedotin | Approved | Phase 3 | 45 | 15 | 6 | 68 | 6 | CA, EU, US | Jun 10, 2019 | Mar 22, 2011 |
| Pirtobrutinib | Approved | Phase 4 | 45 | 27 | 10 | 50 | 7 | CA, EU, US | Jan 27, 2023 | Mar 15, 2019 |
| Brentuximab Vedotin | Approved | Phase 4 | 44 | 19 | 19 | 161 | 16 | CA, EU, US | Aug 19, 2011 | 2004-09 |
| Datopotamab Deruxtecan | Approved | Phase 4 | 44 | 23 | 17 | 46 | 5 | EU, US | Jan 17, 2025 | Mar 1, 2010 |
| Mercaptopurine | Approved | Phase 4 | 43 | 25 | 63 | 169 | 5 | CA, EU, US | Sep 11, 1953 | 1992-10 |
| Fruquintinib | Approved | Phase 4 | 43 | 25 | 11 | 83 | 4 | CA, EU, US | Nov 8, 2023 | 2011-01 |
| Exemestane | Approved | Phase 4 | 42 | 21 | 64 | 199 | 11 | CA, US | Oct 21, 1999 | 1996-05 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.